Performance indicators evaluation of the population-based breast cancer screening programme in Northern Portugal using the European Guidelines

Bento, Maria José; Gonçalves, Guilherme; Aguiar, Ana Teresa; Castro, Clara; Veloso, Vitor; Rodrigues, Víctor

doi:10.1016/j.canep.2015.08.004

Cited by 6 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that rates of mammography nonuse and underuse among women aged 45 to 69 years were higher in the southern regions of Portugal than in the northern region. This finding is in accordance with a recent evaluation of the breast cancer screening program in the northern region of Portugal ( 15 ), which showed a participation rate of 74.5% in 2008–2009 and that most performance indicators were consistent with levels defined by the European Guidelines ( 5 ). However, a report in 2016 on population-based cancer screening programs in Portugal showed that geographic and population coverage and adherence to screening were at lower levels in the northern region than in other regions of Portugal (approximately 80% and 53% vs 98% and 65%, respectively) ( 8 ).…”

Section: Discussionsupporting

confidence: 92%

Mammography Use in Portugal: National Health Survey 2014

Chkotua

Peleteiro

2017

Prev. Chronic Dis.

View full text Add to dashboard Cite

IntroductionUnderstanding the patterns of mammography use and monitoring changes in use are essential to improving national health policy for breast cancer control. We aimed to describe the use of mammography in Portugal and to identify the determinants of its nonuse and underuse by examining data from the National Health Survey 2014.MethodsWe analyzed data on 8,758 women aged 30 years or older. We defined women at an eligible age for mammography as women aged 45 to 69. Women who reported a previous mammography test were classified as ever-users and grouped according to time since the most recent test. We computed the prevalence of mammography use, and we used Poisson regression models to obtain age-adjusted and education-adjusted prevalence ratios and 95% confidence intervals.ResultsThe overall prevalence of mammography use was 80.0%, whereas nonuse was 20.0% and underuse 27.3% among users. The prevalence of nonuse and underuse were lower and associations with sociodemographic characteristics, use of health care services, and behavioral factors were stronger among women aged 45 to 69 than among women aged 30 to 44 and women aged 70 or older. The prevalence of mammography use was generally higher in the northern areas of Portugal than in southern areas and varied by marital status, educational level, and household size. A more frequent use of health care services and healthier behaviors were associated with lower prevalences of both nonuse and underuse.ConclusionThis study illustrates inequalities in mammography use and provides useful information for better allocation of resources in breast cancer screening.

show abstract

Section: Discussionsupporting

confidence: 92%

Mammography Use in Portugal: National Health Survey 2014

Chkotua

Peleteiro

2017

Prev. Chronic Dis.

View full text Add to dashboard Cite

show abstract

“…Also, not all regions follow the same target age for eligible women (25). Except for the North (26), there are no published studies from each regional program, namely for the period 1998–2011, so it is not possible to compare their performance to better help understand our results.…”

Section: Discussionmentioning

confidence: 99%

Breast cancer in Portugal: Temporal trends and age-specific incidence by geographic regions

Lacerda

Kelly

Bastos

et al. 2018

Cancer Epidemiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…15% of all breast cancers, being more prevalent in premenopausal young women (under 40 years old) [ 17 , 18 ]. Due to its aggressiveness and metastatic potential (despite surgical removal of the primary tumour), it has a high risk of recurrence leading to mortality in the first 5 years after diagnosis [ 17 , 19 , 20 ]. The overall survival for women with TNBC is 13.3 months, and less than 30% of the cases survive longer than 5 years [ 15 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Who’s Who? Discrimination of Human Breast Cancer Cell Lines by Raman and FTIR Microspectroscopy

Santos

Martins

Carvalho

et al. 2022

Cancers

View full text Add to dashboard Cite

(1) Breast cancer is presently the leading cause of death in women worldwide. This study aims at identifying molecular biomarkers of cancer in human breast cancer cells, in order to differentiate highly aggressive triple-negative from non-triple-negative cancers, as well as distinct triple-negative subtypes, which is currently an unmet clinical need paramount for an improved patient care. (2) Raman and FTIR (Fourier transform infrared) microspectroscopy state-of-the-art techniques were applied, as highly sensitive, specific and non-invasive methods for probing heterogeneous biological samples such as human cells. (3) Particular biochemical features of malignancy were unveiled based on the cells’ vibrational signature, upon principal component analysis of the data. This enabled discrimination between TNBC (triple-negative breast cancer) and non-TNBC, TNBC MSL (mesenchymal stem cell-like) and TNBC BL1 (basal-like 1) and TNBC BL1 highly metastatic and low-metastatic cell lines. This specific differentiation between distinct TNBC subtypes—mesenchymal from basal-like, and basal-like 1 with high-metastatic potential from basal-like 1 with low-metastatic potential—is a pioneer result, of potential high impact in cancer diagnosis and treatment.

show abstract

Performance indicators evaluation of the population-based breast cancer screening programme in Northern Portugal using the European Guidelines

Cited by 6 publications

References 39 publications

Mammography Use in Portugal: National Health Survey 2014

Mammography Use in Portugal: National Health Survey 2014

Breast cancer in Portugal: Temporal trends and age-specific incidence by geographic regions

Who’s Who? Discrimination of Human Breast Cancer Cell Lines by Raman and FTIR Microspectroscopy

Contact Info

Product

Resources

About